Polypharmacy and mortality among nursing home residents with advanced cognitive impairment: results from the SHELTER study

Graziano Onder, Rosa Liperoti, Giovanni Gambassi, Roberto Bernabei, Daniela Fialova, Eva Topinkova, Henriëtte G. Van Der Roest, Jacob Gindin, Alfonso J. Cruz-Jentoft, Massimo Fini

Research output: Contribution to journalArticle

84 Citations (Scopus)

Abstract

Older adults with advanced cognitive impairment have a limited life expectancy and the use of multiple drugs is of questionable benefit in this population. The aim of the present study was to assess if, in a sample of nursing home (NH) residents with advanced cognitive impairment, the effect of polypharmacy on mortality differs depending on estimated life expectancy.
Original languageEnglish
Pages (from-to)450.e7-450.e7-12
JournalJournal of the American Medical Directors Association
Volume14
DOIs
Publication statusPublished - 2013

Keywords

  • Adrenergic beta-Antagonists
  • Aged
  • Aged, 80 and over
  • Anti-Bacterial Agents
  • Benzodiazepines
  • Cardiotonic Agents
  • Cognition Disorders
  • Digoxin
  • Drug Utilization
  • European Union
  • Female
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Israel
  • Life Expectancy
  • Male
  • Nursing Homes
  • Polypharmacy

Fingerprint

Dive into the research topics of 'Polypharmacy and mortality among nursing home residents with advanced cognitive impairment: results from the SHELTER study'. Together they form a unique fingerprint.

Cite this